Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTG68FB)

• DTT Name: Interleukine 12 (IL-12)
• Gene Name: IL-12
• DTT Type: Clinical trial target; [1]
• UniProt ID: IL12A_HUMAN ; IL12B_HUMAN
• TTD ID: T31072
• KEGG Pathway:
  Cytokine-cytokine receptor interaction (hsa04060)
  Toll-like receptor signaling pathway (hsa04620)
  RIG-I-like receptor signaling pathway (hsa04622)
  C-type lectin receptor signaling pathway (hsa04625)
  JAK-STAT signaling pathway (hsa04630)
  Th1 and Th2 cell differentiation (hsa04658)
  Alcoholic liver disease (hsa04936)
  Type I diabetes mellitus (hsa04940)
  Pertussis (hsa05133)
  Legionellosis (hsa05134)
  Leishmaniasis (hsa05140)
  Chagas disease (hsa05142)
  African trypanosomiasis (hsa05143)
  Malaria (hsa05144)
  Toxoplasmosis (hsa05145)
  Amoebiasis (hsa05146)
  Tuberculosis (hsa05152)
  Measles (hsa05162)
  Influenza A (hsa05164)
  Herpes simplex virus 1 infection (hsa05168)
  Coronavirus disease - COVID-19 (hsa05171)
  Pathways in cancer (hsa05200)
  Inflammatory bowel disease (hsa05321)
  Allograft rejection (hsa05330)
  Lipid and atherosclerosis (hsa05417)
• Reactome Pathway:
  Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807)
  Interleukin-35 Signalling (R-HSA-8984722)
  Interleukin-12 signaling (R-HSA-9020591)
  Interleukin-10 signaling (R-HSA-6783783)

Molecular Interaction Atlas (MIA) of This DTT

6 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABP 654	DM0GXWT	Plaque psoriasis	EA90.0	Phase 3	[2]
Ad-RTS-hIL-12	DMCNTFW	Glioblastoma of brain	2A00.00	Phase 2	[3]
GEN-1	DMJN09S	Ovarian cancer	2C73	Phase 2	[4]
Tavokinogene telseplasmid	DMZX0VF	Melanoma	2C30	Phase 2	[1]
M9241	DMZUM67	Pancreatic cancer	2C10	Phase 1	[5]
MEDI1191	DMD9OVI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
YH010	DMA1T66	Aggressive cancer	2A00-2F9Z	Investigative	[7]

References

• [1] Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540.
• [2] Clinical pipeline report, company report or official report of Amgen
• [3] Clinical pipeline report, company report or official report of Ziopharm Oncology.
• [4] Clinical pipeline report, company report or official report of Celsion.
• [5] Clinical pipeline report, company report or official report of EMD Serono.
• [6] Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298.
• [7] Clinical pipeline report, company report or official report of Biocytogen